Many diseases have at their origin a protein that does not function properly. Now, a multidisciplinary research team with Texas A&M AgriLife and Texas A&M University has found a way to deliver a protein quickly, effectively and briefly to the brain, with therapeutic and scientific implications.
Potential uses for the method in the future could include repairing spinal cord injuries and a range of other localised injection applications.
‘We found that we could successfully deliver a protein into mouse brains,’ said Jean-Philippe Pellois, PhD, professor and associate head of the graduate programme at the Department of Biochemistry and Biophysics at Texas A&M College of Agriculture and Life Sciences. ‘Proteins are large molecules that don’t easily enter cells or cross cell membranes, but we’ve created a trick to achieve this.’
Both the protein and its delivery system degrade naturally after performing their role.
‘We wanted to make sure we had reagents that are very gentle on the cell, that can enter cells without disrupting them and then leave without a trace,’ said Pellois, who is also a researcher at Texas A&M AgriLife Research.
Pellois and his lab collaborated with the lab of Cédric Geoffroy, PhD, assistant professor in the Department of Neuroscience and Experimental Therapeutics at Texas A&M School of Medicine.
Funders of the study included the National Institute of General Medical Sciences, the Cancer Prevention and Research Institute of Texas, the Craig H. Neilsen Foundation, and The Institute for Rehabilitation and Research Foundation.
The findings are published in the journal Science Advances.
How the protein delivery system works
Because proteins can have powerful effects, cells are picky about which proteins they let in. The method the team used to counteract this is a little like mixing vegetables into mac and cheese to tempt a picky kid.
‘Cells have the equivalent of the digestive tract, called the endocytic pathway,’ Pellois said. ‘We are managing to cause a cell to ingest proteins and our delivery tool. The delivery tool, once internalised in the endocytic pathway, then allows the proteins to enter the rest of the cell, particularly the nucleus, where we can trigger a response.’
Other labs have discovered that the human immunodeficiency virus contains a small sequence of amino acids (a peptide) that cells prefer to ingest. The team further improved that peptide’s knack for entering cells. Once inside the cell, the peptide escapes the cell’s ‘digestive tract’, and the target protein comes too.
‘People have used a part of this peptide with a protein of interest,’ Geoffroy said. ‘Our system goes one step further. You don’t have to modify the protein; most will be delivered.’
Mixing the target protein and the peptide in solution, and then injecting the mixture into mouse brains, the team found that their protein readily enters brain cells. The mice were specially bred so that the protein created a visual signal, fluorescence if it arrived as intended. Indeed, brain cells near the injection site began to fluoresce only after the protein and its delivery tool were injected together.
‘If the protein enters cells, these cells become red fluorescent,’ Pellois said. ‘So by simply looking at whether the cells have become fluorescent, we can tell whether the protein has managed to enter.’
Implications for further study
Geoffroy, who specializes in neurotrauma and spinal cord injuries, said the study provides needed evidence that the method works in a living brain.
Further work will focus on improving the method to target just one cell type, he said. Another limitation is that the method currently only works with local injections. Nevertheless, the study opens a path to many potential applications.
‘One key application would be to use this approach for localised injections, such as at the site of a spinal cord injury,’ Pellois said. ‘We are also looking at the possibility of doing this in knee joints for cartilage repair or to fight off the inflammation that diseases like arthritis can cause.’
According to Geoffroy, the method might help deliver therapies other than proteins.
‘This could also enhance the delivery of drugs. If you have an anti-cancer drug, which is very toxic, this method could reduce the amount of drug we deliver,’ he said.
Geoffroy and Pellois have filed a patent on the method’s components. They have also founded a company to take the research closer toward applications.